Therapeutic Area: Oncology
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2020
The clinical efficacy endpoint met for the Phase II trial cohort evaluating selective AXL inhibitor bemcentini- Keytruda combo, in patients with advanced NSCLC who failed checkpoint inhibitor therapy.